Organon & Co. OGN recently announced that the FDA has approved a supplemental New Drug Application, extending the duration of use of NEXPLANON (etonogestrel implant) 68 mg Radiopaque to up to five ... Monthly Prescribing Reference: Nexplanon Approved for Pregnancy Prevention for Up to 5 Years Clinical data support a 5-year duration for the Nexplanon implant, with no reported pregnancies during the extended 2-year study period.
The Food and Drug Administration (FDA) has extended the ... Seeking Alpha: Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque MSN: Organon projects over $1B in Nexplanon revenue for 2025 amid continued expansion CEO Kevin Ali stated that Q1 2025 results met expectations, with Nexplanon achieving double-digit growth and projected to exceed $1 billion in revenue for the year. He highlighted the success of the ... Organon projects over $1B in Nexplanon revenue for 2025 amid continued expansion
